Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-315298

ABSTRACT

Background: To develop and validate a risk-scoring model for predicting severe COVID-19 at presentation. Methods: Entire patients with COVID-19 in three cities in Zhejiang, China from December 2019 to February 2020 were analyzed retrospectively. The risk-scoring model was developed with nomogram using multivariate logistic regression and externally validated by the patients from two other cities near Wenzhou. Findings: Severe COVID-19 was detected 58 out of 488 (11·9%) eligible patients in the primary cohort and 24 out of 153 (15·7%) in the validation cohort. The sex (OR 4·11, 95% CI 1·38 to 14·05), body mass index >25 kg/m2 (OR 6·14, 95% CI 2·05 to 21·29), hypertension (OR 4·97, 95% CI 1·73 to 15·37), neutrophil/lymphocyte ratio (3-6) (OR 8·04, 95% CI 2·51 to 29·52), albumin (35-40) g/L (OR 37·96, 95% CI 5·49 to 825·34) and platelets >300×109/L (OR 6·76, 95% CI 1·55 to 32·47) were independent predictors of severe COVID-19. The risk-scoring model-PAINTS performed excellent discrimination with AUC 0·98, 95% CI 0·96 to 1·00 in the primary cohort and AUC 0·78 (95% CI, 0·67 to 0·89) in the validation cohort. Interpretation: PAINTS score may guide clinical decision-making efficiently and allocate limited medical resources reasonably. Funding: The National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology (CN) [2020ZX09201002];Wenzhou Science and Technology Key Problem Program [ZY2020001];The Primary Research and Development Plan of Zhejiang Province [2019C03011] and the Natural Science Foundation of Zhejiang Province [LQ20H150002].Declaration of Interest: None to declare. Ethical Approval: The study was conducted under the amended Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Wenzhou Medical University (No.2020-002). The written consent was waived by the Institutional Review Board (IRB) of Wenzhou Medical University (No.2020-002)

2.
Comput Struct Biotechnol J ; 19: 1863-1873, 2021.
Article in English | MEDLINE | ID: covidwho-1171610

ABSTRACT

Metabolic profiling in COVID-19 patients has been associated with disease severity, but there is no report on sex-specific metabolic changes in discharged survivors. Herein we used an integrated approach of LC-MS-and GC-MS-based untargeted metabolomics to analyze plasma metabolic characteristics in men and women with non-severe COVID-19 at both acute period and 30 days after discharge. The results demonstrate that metabolic alterations in plasma of COVID-19 patients during the recovery and rehabilitation process were presented in a sex specific manner. Overall, the levels of most metabolites were increased in COVID-19 patients after the cure relative to acute period. The major plasma metabolic changes were identified including fatty acids in men and glycerophosphocholines and carbohydrates in women. In addition, we found that women had shorter length of hospitalization than men and metabolic characteristics may contribute to predict the duration from positive to negative in non-severe COVID-19 patients. Collectively, this study shed light on sex-specific metabolic shifts in non-severe COVID-19 patients during the recovery process, suggesting a sex bias in prognostic and therapeutic evaluations based on metabolic profiling.

3.
Neuropsychiatr Dis Treat ; 16: 2661-2667, 2020.
Article in English | MEDLINE | ID: covidwho-954302

ABSTRACT

OBJECTIVE: The WHO has upgraded the status of coronavirus disease 2019 (COVID-19) from epidemic to global pandemic. The psychometric properties aspects of COVID-19 patients without comorbidities in the short term after discharge have not been reported. In this study, the Short Form 36 (SF-36) was used to evaluate the psychometric properties and to find relevant risk factors. METHODS: The study was conducted in seven hospitals from January 2020 to April 2020. The SF-36 questionnaire was administered one month after discharge. Univariate analysis and multivariate regression model were used to analyze the risk factors of psychometric properties impairment. RESULTS: In univariate analysis of independent risk factors, according to the comparison of whether the duration of positive nucleic acid was greater than 20 days, the positive nucleic acid duration was independently related to the decreased role-emotional value [100, IQR (66-100) vs 100, IQR (0, 100); p = 0.0156]. In addition, multivariable linear regression model showed that male sex and positive nucleic acid duration were related to decreased role-emotional value (p = 0.03< 0.05; p = 0.01< 0.05, respectively). Mental health was associated with age (p= 0.0435). Subsequently, we divided into three subgroups: less than seven days, 7 to 14 days and more than 14 days according to the positive nucleic acid duration. The results revealed that there were significant differences in the vitality value and mental health value of patients aged 46 to 69 in the subgroup where the positive nucleic acid duration longer than 14 days (p= 0.0472; p= 0.0311< 0.05, respectively). Similarly, there are also significant differences in role-emotional value in different genders (p= 0.0316). CONCLUSION: The study described the psychometric properties of COVID-19 patients without comorbidities shortly after discharge. Risk factors for psychometric properties damage included age, male sex, and nucleic acid duration.

5.
Clin Transl Sci ; 13(6): 1096-1102, 2020 11.
Article in English | MEDLINE | ID: covidwho-742071

ABSTRACT

This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for the treatment of mild or moderate coronavirus disease 2019 (COVID-19) and to explore its clinical efficacy and safety. Patients with mild or moderate COVID-19 were randomly divided into the BRH group or the control group at a 2:1 ratio. Routine treatment according to China's Novel Coronavirus Pneumonia Diagnosis and Treatment Plan was performed in both groups, whereas patients in the BRH group were additionally given oral BRH (32 mg t.i.d.) for 14 consecutive days. The efficacy and safety of BRH were evaluated. A total of 18 patients with moderate COVID-19 were randomized into the BRH group (n = 12) or the control group (n = 6). There were suggestions of BRH advantage over placebo in improved chest computed tomography, need for oxygen therapy, and discharge rate within 20 days. However, none of these findings were statistically significant. BRH tablets may potentially have a beneficial effect in patients with COVID-19, especially for those with lung or hepatic injury. A further definitive large-scale clinical trial is feasible and necessary.


Subject(s)
Bromhexine/therapeutic use , COVID-19/drug therapy , SARS-CoV-2 , Adult , Bromhexine/adverse effects , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pilot Projects , Tablets
SELECTION OF CITATIONS
SEARCH DETAIL